AH

Albert Hansen

Island Pharmaceuticals Limited | Non-Executive Director
Mr Hansen is currently President of KESA Partners, Inc. ("KESA") a family investment office focused on seed investing in life science-related startups. KESA provides capital and strategic management to its portfolio companies. Mr. Hansen serves as President of one of KESA"s portfolio companies, Clearlight Biotechnologies, Inc., which has licensed imaging technology for tissue analysis from Stanford University. From 2001 to 2012, Mr. Hansen was a Managing Director of Signet Healthcare Partners, a growth capital private equity firm focused on emerging life science companies. Mr. Hansen has over 25 years of private equity investment experience, with almost 20 years in the life sciences/pharmaceutical field. Mr. Hansen was a principal of Darby Overseas, since acquired by Franklin Templeton. He was also a political appointee as Director of Corporate Finance at the U.S. Treasury Department in 1992. Earlier in his career, Mr. Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. He was also an investment banker at E.F. Hutton & Co. Mr. Hansen also served in the U.S. Army as an Infantry and Special Forces officer.

Company and Role

Company
Title
Tenure
Since
ILA
Island Pharmaceuticals Limited
  • Non-Executive Director
3yrs, 6mthOct 2020

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ILA
Island Pharmaceuticals Limited
26/03/24N/A11,104,034566,667N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ILA
Island Pharmaceuticals Limited
26/03/24
Issued
166,667$0.060$10,000Rights issue
ILA
Island Pharmaceuticals Limited
26/03/24
Issued
166,667$0.060$10,000Rights issue
ILA
Island Pharmaceuticals Limited
04/04/23
Expiry
23,030$0.070$1,612Options expired
ILA
Island Pharmaceuticals Limited
18/11/21
Issued
100,000$0.250$25,000Director remuneration